A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Inclusion Criteria:

• Participants must be diagnosed with advanced epithelial ovarian cancer, primaryperitoneal cancer or fallopian tube cancer

• Participants must have folate receptor alpha positive tumor expression as defined inthe protocol

• Participants must have platinum-resistant ovarian cancer, defined as progressionwithin 6 months from completion of a minimum of four cycles of platinum-containingtherapy.

• Participants must have received at least one but no more than three prior systemictreatment regimens and for whom single-agent chemotherapy is appropriate as the nextline of treatment

• Participants must have at least one lesion that meets the definition of measurabledisease by RECIST 1.1

Exclusion Criteria:

• Diagnosis of clear cell, low grade ovarian cancer or mixed tumors

• Participants with primary platinum-refractory disease

• Serious concurrent illness or clinically relevant active infection as defined in theprotocol

• Prior treatment with mirvetuximab soravtansine

• Women who are pregnant or breast feeding